α-Klotho

Dr. Kuro-o to speak at Second Annual Entrepreneurship, Longevity and Biotech Conference Held in Boca Raton, FloridaBOCA RATON, Fla. and VIENNA, Austria, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, a pioneer in developing therapies for neurodegenerative conditions by addressing the biology of aging, today announced the appointment to its Scientific Advisory Board of Professor Makoto Kuro-o, a pioneer in the science of aging and longevity and the first to identify the klotho gene. In addition, ADvantage’s CEO, Jeffrey Madden, will provide updates on the development of ADvantage’s lead compound, AD04™, now in phase 2 clinical trials in Alzheimer’s Disease patients, and on the company’s work on the klotho protein, which aims to reduce the effects of aging. Kuro-o and Madden will speak at the invite-only Entrepreneurship, Longevity, and Biotech Conference in Boca Raton on February 9 and 10. The conference assembles biotech and longevity scientists and entrepreneurs to share research and exchange ideas for improving the biotech and longevity industries. Last year, Moderna co-founder Professor Robert Langer gave the keynote address. “The biology of aging is growing in prominence as scientists discover how damage accumulates throughout the body and how some factors, such as the klotho protein, rejuvenate and protect multiple systems,” said Madden. “ADvantage is working to reduce the burden of aging in Alzheimer’s specifically and other age-related conditions more generally, and Dr. Kuro-o will be a tremendous addition in that effort. His discovery of the klotho gene opened a new field that we will work together to advance. Makoto Kuro-o, M.D., Ph.D. is a professor at the Center of Molecular Medicine, Jichi Medical University, Japan. He has more than 30 years of research and clinical experience in endocrinology, endocrine fibroblast growth factors, molecular biology of aging, nephrology, and mineral metabolism. He discovered and named the klotho gene in 1997, and since then has written and published extensively on the topic. His pioneering research has opened new and promising paths toward understanding longevity as well as preventing and treating disease. Dr. Kuro-o received his degrees from the University of Tokyo, Japan. Other speakers at this year’s conference include Dr. Carmela Abraham, Chief Science Officer, ADvantage Therapeutics, Dr. Rudy Tanzi, Professor of Neurology, Harvard Medical School and Director of the Genetics and Aging Research Unit, MGH, Dr. Leona Krohle CEO and Founder, Bluezone Longevity Sphere, Nathan Cheng, General Partner, Healthspan Capital, Lisa Fabiny-Kiser, CEO, SENS Research Foundation, Agustin Fernandez III, CEO, Rational Vaccines, Iosif Gershteyn, CEO, ImmuVia, Bryan Johnson, Founder and CEO, Blueprint, Jeff Madden, CEO, ADvantage Therapeutics, Fiona Miller, Managing Partner, QuadraScope, Jim O'Neill, Co-founder, the Thiel Fellowship, Former HHS Official, Dr. Achim Schneeberger, Chief Medical Officer, ADvantage Therapeutics, Yuri Deigin, Co-Founder, YouthBio Therapeutics, Petr Sramek, CEO, healthylongevity.clinic, Managing Partner, Longevitytech.fund, Dr. Jean Hebert, Professor, Albert Einstein College of Medicine, Daniel Gropper, Dean, FAU College of Business, Dr. Siri Terjesen, Phil Smith Professor, Associate Dean of Research & External Relations, Executive Director, Madden Center for Value Creation at Florida Atlantic University, Leonardo Ferreira, Professor at Medical University of South Carolina. Jonathan Gootenberg, McGovern Fellow at MIT, Omar Abudayyeh, McGovern Institute Fellow at MIT, Andre Watson, Chairman and CEO, Ligandal, and other biotech visionaries. Sponsored by the Madden Center for Value Creation at FAU’s College of Business and in collaboration with FAU Health, the conference is being held February 9th and 10th on the FAU campus in Boca Raton, Florida. About AD04™ADvantage Therapeutics is developing AD04™ as a novel immunotherapy for mild Alzheimer’s Disease. The compound has been used extensively as an adjuvant in human and animal vaccination programs. In a previous trial, AD04™ serving as a control against another compound appeared to demonstrate statistically significant slower decline in cognitive and quality of life clinical measures compared to other treatment groups. AD04™ also showed slower decline in hippocampal volume as a biomarker. The Company believes that rather than being limited to a specific aspect of AD pathology, such as amyloid beta or tau, AD04™ may address inflammatory mechanisms in the brain, functioning as an immunomodulator, stimulating and/or regulating the immune system to reduce AD pathology. About Alzheimer’s DiseaseAbout fifty million people worldwide suffer from Alzheimer’s Disease, which is the sixth leading cause of death in industrialized countries. In 2019, the World Health Organization estimated the total worldwide cost of dementia at $1.3 trillion and expects this cost to rise to $2 trillion by 2030. The socio-economic burden of Alzheimer’s Disease is enormous. AD devastates the lives of patients and their families. AD victims lose their memory and independence. Alzheimer’s Disease is a high unmet medical need as there are currently no disease-modifying drugs approved worldwide. The availability of a safe, effective, affordable drug would transform the life of an AD patient from accepting a debilitating disease to the retention of personality, independence, and dignity. About ADvantage Therapeutics, Inc.Headquartered in the Wynwood neighborhood in Miami, ADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a central focus on Alzheimer’s Disease. The Company’s lead compound AD04™ is a subcutaneous injectable therapy that entered, in November 2023, confirmatory Phase 2b clinical trials in Europe, to evaluate its safety and efficacy in early AD patients. The Company believes that AD04™ may function as an immunomodulator, stimulating and regulating the immune system to reduce AD pathology, rather than limiting therapy to attack the misfolded proteins, beta amyloid and tau. The Company is exploring additional approaches to mitigating neurodegenerative disease, among them increasing the levels of Klotho, a life and health extending protein which will have an overall impact on longevity. About ADvantage Therapeutics GmbHADvantage Therapeutics GmbH, founded in 2021, is the Vienna BioCenter-based subsidiary of ADvantage Therapeutics, Inc., where the Company conducts early research and drug development. Safe Harbor-Forward-Looking StatementsThis press release may contain forward-looking statements, including statements of potential mode of action, potential clinical effect, potential safety, and ADvantage’s potential clinical development program and pipeline program. ADvantage is in the early stages of developing and testing its AD04™ compound and may not receive future regulatory approvals needed for marketing it as a drug. The described clinical effect of our lead compound AD04™ is primarily based on results of a Phase 2 study designed to evaluate a different compound. The described results need to be confirmed for proof of concept, might not be representative of larger scale clinical trials, and do not guarantee future clinical success. Any preclinical results presented here are interim. The mechanism of action of AD04™, as potentially determined in our future investigations, particularly in future clinical trials with patients with Alzheimer’s Disease, might differ from the one presented. Contacts:For ADvantage Therapeutics195 NW 40th StreetMiami, FL 33127 Jeffrey Madden CEOjeff@advantagetherapeutics.com(305) 846-9027 David Buchsbaum CFOdavid@advantagetherapeutics.com(305) 846-9027

Klogenix co-founder, Dr. Carmela Abraham, joins ADvantage Therapeutics, Inc. as Chief Science OfficerBOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Klogenix LLC (“Klogenix” or “the Company”) is pleased to announce that its intellectual property portfolio has been acquired by ADvantage Therapeutics, Inc. and co-founder Dr. Carmela R. Abraham, Ph.D. has been appointed Chief Science Officer at the acquiring company. Dr. Abraham, a distinguished luminary in the fields of Alzheimer’s disease and aging, brings her wealth of knowledge and pioneering work on the Klotho protein to the forefront of ADvantage’s strategic vision. ADvantage Therapeutics Inc. is currently entering confirmatory Phase 2b clinical trials with its AD04 Alzheimer’s drug candidate, developed at its labs at the Vienna, Austria, BioCenter. Commenting on her new role, Dr. Abraham stated, “Through ADvantage Therapeutics’ pioneering compound AD04, and our exploration of the Klotho protein's applications, we are at the forefront of redefining approaches to combat Alzheimer’s disease and the aging process. Having dedicated my entire career to these goals, I am delighted to join the talented team of scientists at ADvantage and contribute to addressing some of the most complex challenges that affect the human body and mind. I eagerly anticipate our collaborative journey ahead." AD04™ is a novel disease modifying immunomodulator for mild Alzheimer’s Disease. The compound has been shown in a previous trial to significantly slow the decline in patients’ cognition and quality of life as well as slow the decline in hippocampal volume (as a biomarker). ADvantage Therapeutics, Inc. believes AD04™ stimulates and/or regulates the immune system to reduce Alzheimer’s pathology. ADvantage Therapeutics is dedicated to advancing the science of neurodegenerative diseases and committed to developing innovative therapies that can make a meaningful difference in the lives of patients and their caregivers. For more information on ADvantage Therapeutics, Inc., and its pipeline please visit www.advantagetherapeutics.com. Menachem Abraham, co-founder and CEO of Klogenix commented, “We are excited to see our research move to the next phase as part of a clinical stage company with excellent strategic fit. ADvantage with its talented scientists will be an excellent home for our projects.” Carmela R. Abraham, Ph.D., has dedicated her entire career to unraveling the intricacies of aging and Alzheimer’s disease. She holds a B.Sc. in Biology from Tel Aviv University and a Ph.D. in Neuroscience from Harvard University. As a Professor Emerita of Biochemistry and Pharmacology & Experimental Therapeutics at Boston University School of Medicine, Dr. Abraham's research has been instrumental in identifying the neuroprotective, anti-oxidative, and anti-inflammatory properties of the Klotho protein, which experiences diminished levels with age. The groundbreaking work of her team has shown that elevating Klotho levels can enhance outcomes in mouse models of Alzheimer's disease, multiple sclerosis, and ALS. Dr. Abraham was the first Rappaport fellow at the Center for Neurologic Diseases at Brigham and Women’s Hospital and received prestigious awards, including the Zenith and Temple awards from the Alzheimer’s Association. Her research has received support from esteemed organizations such as the NIH, Alzheimer’s Association, Boston University’s Ignition Award, the Massachusetts Neuroscience Consortium Award, the Cure AD Fund, and Alzheimer’s Drug Discovery Foundation. About Klogenix LLC. Klogenix is a Boston based pre-clinical stage biotech company targeting prevention and treatment of age-related diseases and extension of healthy lifespans. The company has been focused on the Klotho resilience and longevity gene since its inception. Klogenix pioneered development of several advanced modalities for upregulating endogenous Klotho as well as delivery of exogenous Klotho genetic material. About Alzheimer’s Disease. About forty-four million people worldwide suffer from Alzheimer’s Disease; it is the sixth leading cause of death in industrialized countries. In 2019, the World Health Organization estimated the total worldwide cost of dementia at $1.3 trillion and expects this cost to rise to $2 trillion by 2030. Recent FDA approval of the first disease modifying drugs for Alzheimer’s is encouraging but much more is needed. Combination treatments with multiple targets will likely lead to more effective therapies. At this time Alzheimer’s Disease remains an unmet medical need. The socio-economic burden of Alzheimer’s Disease is enormous as it devastates the lives of patients and their families. About ADvantage Therapeutics. ADvantage, headquartered in Miami, Florida, is developing therapies to treat neurodegenerative conditions with a central focus on Alzheimer’s disease. Its lead compound AD04™ is an injectable therapy in the process of entering a confirmatory Phase 2b clinical trial in Europe, to evaluate its safety and efficacy in mild Alzheimer’s Disease. ADvantage believes that AD04™ may function as an immunomodulator, stimulating and regulating the immune system to reduce Alzheimer’s pathology, rather than limiting therapy to the clearing of aggregated proteins. ADvantage, at its Vienna BioCenter based subsidiary, is exploring additional approaches to mitigating neurodegenerative diseases, which it believes will eventually have an overall impact on longevity. Contact: Menachem AbrahamCEOKlogenix LLCmeabraham1@icloud.com781 718 5102

ADvantage also acquires intellectual property to enhance its Alzheimer’s disease and longevity portfoliosMIAMI, Oct. 02, 2023 (GLOBE NEWSWIRE) -- In a transformative move bolstering its position in the realm of neurodegenerative therapies and Alzheimer’s disease (AD) research, ADvantage Therapeutics, Inc. today announced the appointment of Carmela R. Abraham, Ph.D. as its Chief Science Officer. Dr. Abraham, a luminary in the fields of AD and aging, will complement ADvantage’s efforts to extend healthspan by delivering proprietary klotho-encoding mRNA. As part of this development, ADvantage Therapeutics has acquired important intellectual property assets including four patent applications from Klogenix, which Dr. Abraham co-founded with Menachem Abraham. "Dr. Abraham is an internationally recognized authority in AD research, and we eagerly anticipate the invaluable contributions she will make to our development programs and strategic direction as we continue to explore the rejuvenation potential of klotho,” said Jeffrey Madden, ADvantage’s Chief Executive Officer. “The assets from Klogenix will further empower our research. On behalf of our management team and board of directors, I extend a warm welcome to her." Dr. Abraham has dedicated her career to unraveling the intricacies of aging and Alzheimer’s disease. She holds a B.Sc. in Biology from Tel Aviv University and a Ph.D. in Neuroscience from Harvard and is Professor Emerita of Biochemistry and Pharmacology & Experimental Therapeutics at Boston University School of Medicine. Dr. Abraham's research has been instrumental in identifying the neuroprotective, anti-oxidative, and anti-inflammatory properties of the klotho protein, a rejuvenating protein whose serum levels decline with age. Her groundbreaking work has shown that elevating klotho levels can enhance outcomes in mouse models of Alzheimer's disease, multiple sclerosis, and ALS. During 43 years studying normal aging and Alzheimer's disease, Dr. Abraham has concentrated on identifying disease-modifying pharmaceutical interventions that can prevent or alleviate the symptoms of AD and other age-related conditions, such as cancer and kidney disease. Prior to joining ADvantage, she co-founded Klogenix. Dr. Abraham was the first Rappaport fellow at the Center for Neurologic Diseases at Brigham and Women’s Hospital and received prestigious awards, including the Zenith and Temple awards from the Alzheimer’s Association. Her groundbreaking research has received support from organizations such as the NIH, the Alzheimer’s Association, Boston University’s Ignition Award, the Massachusetts Neuroscience Consortium Award, the Cure AD Fund, and Alzheimer’s Drug Discovery Foundation. “Through ADvantage Therapeutics’s pioneering compound AD04, and our exploration of the klotho protein's applications, we are at the forefront of redefining approaches to combat Alzheimer’s disease and the aging process,” said Dr. Abraham. “Having dedicated my career to these goals, I am delighted to join the team and address some of the most complex challenges that affect the human body and mind. I eagerly anticipate our collaborative journey ahead." ADvantage Therapeutics is dedicated to advancing the science of neurodegenerative diseases and committed to developing innovative therapies that can make a meaningful difference in the lives of patients. For more information on ADvantage Therapeutics, Inc., please visit www.advantagetherapeutics.com About AD04™ADvantage is developing AD04™ as a novel immunomodulator for mild AD. The compound has been used as an adjuvant in human and animal vaccination programs. Serving as a control against another compound in a previous trial, AD04™appeared to demonstrate statistically significant slower decline over other treatment groups in cognitive and quality of life clinical measures in Alzheimer’s patients. Treatment with AD04™ also showed slower decline in hippocampal volume as a biomarker. ADvantage believes that rather than being limited to a specific aspect of AD pathology, such as amyloid beta or tau, AD04™ functions as an immunomodulator in the brain and at the periphery, stimulating and/or regulating the immune system to reduce AD pathology. About Alzheimer’s DiseaseAbout forty-four million people worldwide suffer from AD, the sixth leading cause of death in industrialized countries. In 2019, the World Health Organization estimated the total worldwide cost of dementia at $1.3 trillion and expects this cost to rise to $2 trillion by 2030. The socio-economic burden of Alzheimer’s disease is enormous. AD devastates the lives of patients and their families. The patients lose their memories and independence, and the loss of a loved one leaves behind guilt, grief, and anger. Treating or delaying Alzheimer’s disease is a high unmet medical need as there are currently no disease-modifying drugs approved worldwide. The availability of a safe, effective, affordable drug would transform the life of AD patients from accepting a debilitating disease to the retention of personality, independence, and dignity. About ADvantage TherapeuticsHeadquartered in the Wynwood neighborhood of Miami, ADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a central focus on Alzheimer’s disease. ADvantage’s lead compound AD04™ is an injectable therapy about to begin a confirmatory Phase 2b clinical trial in Europe to evaluate safety and efficacy in mild Alzheimer’s disease. ADvantage believes that AD04™ may function as an immunomodulator, stimulating and regulating the immune system to reduce AD pathology, rather than limiting therapy to the misfolded and aggregated amyloid beta and tau proteins. ADvantage is also exploring additional approaches to mitigating neurodegenerative disease, which it believes will eventually extend longevity. About ADvantage Therapeutics GmbHADvantage Therapeutics GmbH, founded in 2021, is the Vienna BioCenter-based subsidiary of ADvantage Therapeutics, Inc., where the Company conducts early research and drug development. ADvantage is developing therapies to treat neurodegenerative conditions like Alzheimer’s disease (AD) and is currently preparing for clinical trials in Europe and in the U.S. Safe Harbor and Forward-Looking StatementsThis press release may contain forward-looking statements, including statements of potential mode of action, potential clinical effect, potential safety, and ADvantage’s potential clinical development program and pipeline program. ADvantage may be unable to achieve the expected benefits of the topics described in this press release. ADvantage may be unsuccessful in having any of the purchased patent applications result in issued patents with the full desired claims or at all. ADvantage may not receive the expected synergies from these transactions. ADvantage is in the early stages of developing and testing its AD04™ compound and may not receive regulatory approval to conduct the contemplated Phase 2b trial. The described clinical effect of our lead compound AD04™ is primarily based on results of a Phase 2 study designed to evaluate a different compound. The described results need to be confirmed for proof of concept, might not be representative of larger scale clinical trials, and do not guarantee future regulatory approval or clinical success. Any preclinical results presented are interim. The mechanism of action of AD04™ as potentially determined in our future investigations, particularly in future clinical trials with patients with AD, might differ from the one presented. Contacts: For ADvantage Therapeutics195 NW 40th StreetMiami, FL 33127Jeffrey Madden CEOjeff@advantagetherapeutics.com(786) 542-5499 David Buchsbaum CFOdavid@advantagetherapeutics.com(786) 542-5499 For Media:Jules AbrahamJQA Partners, Inc.jabraham@jqapartners.com(917) 885-7378(Jules Abraham is not related to Carmela Abraham)